Tolerability associated with sunitinib (SU) 2-week on and 1-week off schedule (2/1 schedule) compared with its standard schedule in metastatic RCC (mRCC): Meta-analysis
نویسندگان
چکیده
منابع مشابه
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial
BACKGROUND AND PURPOSE FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions. MATERIAL AND METHODS Patients were randomly allocated to 40Gy/...
متن کاملModified Schedule Sunitinib in Metastatic Renal Cell Carcinoma
Background: New targeted therapies have revolutionized the treatment landscape of metastatic renal cell carcinoma over the last decade. Sunitinib has demonstrated high activity in renal cell carcinoma (RCC), still complete remission is not a common occurrence in patients. In patient achieving complete response, continuation of therapy beyond complete response is debatable. Cytoreductive nephrec...
متن کاملSunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma.
PURPOSE To assess the efficacy and tolerability of sunitinib dosing schedule of 2 weeks on and 1 week off (schedule 2/1) vs. the traditional schedule of 4 weeks on and 2 week off (schedule 4/2) and its influence on health-related quality of life (HRQoL) in Chinese patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS A retrospective analysis of 108 patients with mRCC who...
متن کاملSunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
Sunitinib is an inhibitor of platelet-derived growth factors receptor (PDGFR) and vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine-kinase activities, and it is registered for the treatment of metastatic renal cell carcinoma (mRCC). Indeed, sunitinib 50mg/day for 28 days every 6 weeks is effective against mRCC and induces significant improvements in progression-free and overall su...
متن کاملContents 1 Schedule 4 2
In this talk we will present recent developments in the design and analysis of numerical homogenization methods. Numerical methods for linear and nonlinear partial differential equations that combine multiscale methods with reduced order modeling techniques such as the reduced basis method will be discussed. The talk is based upon a series of joint works with various collaborators[1,2,3,4,5]. [...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2016
ISSN: 0923-7534
DOI: 10.1093/annonc/mdw373.48